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ORIGINAL RESEARCH
Abstract: The purpose of this open multicenter study of 4771 patients with a DSM-IV
diagnosis of Major Depressive Episode was to analyse the response to mirtazapine in general
practice and primary care. Patients with a baseline score of at least 20 on the Montgomery-
Asberg Depression Rating Scale (MADRS) were treated with mirtazapine for 6 weeks
(30 mg/day) and clinically assessed by their psychiatrists at weekly intervals through the
MADRS and Clinical Global Improvement (CGI) rating scales. The data analysis was carried
out on an “intent-to-treat” basis to collect outcome information on all patients. Our results
suggested that the efficacy of the antidepressant effect relates to a nonspecific process. Nearly
all patients (95%) showed at least slight improvement at the end of the observation period,
while the response to treatment was independent of the clinical forms of depression. In
particular, all measures of efficacy displayed the maximum change within the first 2 weeks of
treatment, with further improvement occurring at much slower rates. Significant improvement
within the first 2 weeks of treatment was highly predictive of the final response, and can serve
as a guideline for clinicians when deciding about increased dosage, augmentation, or change
of medication in unresponsive patients. Detailed analyses of individual MADRS items showed
that mirtazapine’s pharmacological profile, unlike selective serotonin reuptake inhibitors, led
relatively quickly to a significant reduction of suicidal thoughts, a fact of particular clinical
relevance.
Keywords: depression, antidepressive agents, mirtazapine, treatment outcome, prognosis,
suicide
Introduction
Mirtazapine is an antidepressant with a novel mode of action: it enhances
noradrenaline and serotonin neurotransmission by its direct action on various alpha-
adrenergic and serotonergic receptors. Mirtazapine increases the release of
noradrenaline by blocking the alpha-2 presynaptic adrenoceptors (De Boer and Ruigt
1995). The increase of intrasynaptic noradrenaline concentrations activates in turn
the alpha-1 adrenoceptors located on serotonergic neurons. Alpha-1 adrenoceptors
increase the firing rate of serotonergic neurons (Haddjeri et al 1995, 1998) and the
release of serotonin at the nerve terminals (De Boer et al 1995). In addition, by
blocking alpha-2 heteroreceptors at the serotonergic nerve terminals, mirtazapine
prevents the inhibitory effect of noradrenaline on serotonin release, which leads to
further serotonin release (De Montigny et al 1995). Mirtazapine binds also with high
antagonist affinity to the 5-HT2, 5-HT3, and H1 receptors. This prevents the
overexcitation of serotonergic neurons and adds a sedative component to the spectrum
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of pharmacological actions of the drug. On the hormonal
level, mirtazapine, unlike other antidepressants, decreases
the release of corticotrophin (Schule et al 2002) and cortisol
(Laakmann et al 2000).
Mirtazapine has been shown to be an efficacious
antidepressant. Previous studies comparing mirtazapine with
placebo have shown greater improvement of depressive
symptoms with mirtazapine as early as the first week of
treatment (Kasper 1995). Studies comparing mirtazapine
with other antidepressants have demonstrated comparable
efficacy: amitriptyline (Smith et al 1990; Bremner 1995;
Zivkov and de Jongh 1995; Hoyberg et al 1996; Mullin et
al 1996), clomipramine (Richou et al 1995), doxepin
(Marttila et al 1995), fluoxetine (Wheatley et al 1998),
citalopram (Leinonen et al 1999), paroxetine (Benkert et al
2000), sertraline (Behnke et al 2003), and venlafaxine
(Guelfi et al 2001). All studies comparing mirtazapine with
selective serotonin reuptake inhibitors (SSRIs) consistently
showed a higher efficacy for mirtazapine in the early phases
of treatment. The differences were significant at week 1
compared with paroxetine (Benkert et al 2000); at weeks 1
and 2 compared with sertraline (Behnke et al 2003); at week
2 compared with citalopram (Leinonen et al 1999); and at
weeks 3 and 4 compared with fluoxetine (Wheatley et al
1998).
The main purpose of this study was to look at the time
characteristics of improvement under mirtazapine in a
naturalistic setting that reflects everyday clinical practice
more realistically than controlled randomized studies do.
We used an open-label design and included both outpatients
and inpatients. To characterize the profile of clinical effects
of mirtazapine, we analyzed: (1) the response to treatment
in the total population as well as in clinically characterized
subtypes of depression; (2) the effect of baseline severity
on treatment response; (3) the chronology of the response
(early improvement and prediction of response); and (4)
the rates of change in single symptoms during treatment.
Methods
Sample
This open-label, prospective, multicenter study was carried
out in France, under the naturalistic conditions of primary
care in either psychiatric private practice (n = 4037 patients)
or in hospital settings (n = 734 patients). Fees to psychiatrists
were paid by Organon-France. In total, 4771 patients were
recruited in 1185 centers.
Selection of patients
Inclusion criteria. Patients had to be 18 years or older, suffer
from a DSM-IV major depressive episode, and display a
minimum score of 20 on the Montgomery and Asberg
Depression Rating Scale (MADRS) (Montgomery and
Asberg 1979). Patients had to declare that they understood
the goal of the study and gave their informed written consent.
Exclusion criteria. Nonstabilized somatic disease
(seizures, renal, or hepatic insufficiency), history of blood
dyscrasias, known allergic reaction to mirtazapine, current
suicidal risk (according to the physician’s judgment),
pregnancy, breastfeeding, no contraception in women of
reproductive age, current depressive episode of more than
1 year’s duration or nonresponse to 2 antidepressant
treatments, and monoamine oxidase inhibitor treatment
during the previous 2 weeks.
Treatment
Mirtazapine was given over 6 weeks in a dose of
30 mg/day at bedtime (mean recommended dosage by the
French registration authorities). Other psychotropic
medication(s) (for instance benzodiazepines) prescribed for
more than a month before inclusion were kept unchanged.
Changes in psychotropic medications were allowed after
the first week of treatment and were recorded. Somatic
treatments were continued with dosages adapted as needed.
Diagnosis and measures
The diagnosis of depression was made according to DSM-
IV criteria for major depressive episode. Patients were
further characterized with DSM-IV specifiers for
melancholy, atypical depression, severity (mild, moderate,
severe with psychotic symptoms, severe without psychotic
symptoms), and recurrence. Postpartum depression and
seasonal depression were also diagnosed according to DSM-
IV. The suicidal attempt group was defined as patients having
a history of at least 1 suicide attempt. The bipolar feature
group was defined by a history of cyclothymia or manic/
hypomanic episodes.
The severity of depression was assessed at baseline with
the MADRS, and at weeks 1, 2, and 6 with the MADRS
and the Clinical Global Impression-Improvement scale
(CGI-I) (Guy 1976). Anxiety was assessed with the Covi
scale (Covi et al 1979) at baseline and weeks 1, 2, and 6.
The investigators were not specifically trained in the use of
the MADRS, CGI, or Covi scales because of the naturalisticNeuropsychiatric Disease and Treatment 2005:1(1) 61
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nature of the study design. There were also no tests of inter-
rater reliability.
Criteria for improvement, response, and
remission
In this paper, “improvement” refers to the early changes in
the first 2 weeks and “response” refers to changes after 6
weeks of treatment. Improvement was defined as the
percentage decrease on the MADRS or a 1-point increase
on the CGI-I scale. Response was defined as a 50% decrease
on the MADRS or a 2-point increase on the CGI-I scale.
“Sustained” improvement or response are changes that
persisted up to 6 weeks and were assessed as decreases in
MADRS score in the range of –15% to –60%. Remission is
defined as a MADRS global score of less than 10 points.
Statistics
The data analysis was carried out on the “intent-to-treat”
basis (ITT) to include all available information on all
patients.
At baseline, qualitative data were analysed by the chi-
square test statistic and quantitative data by Wilcoxon tests.
The time course of improvement and response was analysed
using survival analysis, Cox models, and two-way ANOVAs
(analysis of variance) or ANCOVAs (analysis of covariance).
All correlations were evaluated through Pearson Product-
Moment coefficients.
Analyses of MADRS global scores, MADRS items,
remission, speed of change (defined as the percentage
change per day), and anxiety scores were carried out in the
ITT population with missing data having been compensated,
where necessary through the Last Observation Carried
Forward (LOCF) procedure. The relative change of MADRS
items was compared with the paired t-test. Changes in item
scores were calculated with ANOVA. Descriptive statistics
were used to compare the speed of score reduction.
Statistical tests were two-sided, and significance level was
set to p < 0.05.
Results
At baseline
In all, 4768 patients (68% females) with mean age 45 ± 12
were treated. At baseline the mean MADRS score was
31.5 ± 6.1 (mean ± SD). The severity defined by DSM-IV
criteria was mild in 1.4%, moderate in 36.5%, severe without
psychotic features in 59.8%, and severe with psychotic
features in 2.3% of the cases. Fifty-three percent of patients
suffered from their first depressive episode; the remaining
47% from a recurrent episode. Atypical depression, post-
partum depression, and melancholic depression, defined by
DSM-IV criteria, were present in 6.4%, 0.6%, and 15.8%,
respectively. The frequency of other seasonal depression
was 15.2% among the cases of recurrent depression. The
mean number of previous depressive episodes was 3.4 ± 3.1,
and of past suicidal attempts 2.0 ± 2.0.
The mean scores and standard deviations of single
MADRS items were: “apparent sadness” 3.8 ± 1.0; “reported
sadness” 3.8 ± 0.9; “inner tension” 3.5 ± 0.9; “reduced sleep”
3.2 ± 1.4; “reduced appetite” 2.0 ± 1.6; “concentration
difficulties” 3.4 ± 1.0; “lassitude” 3.7 ± 1.0; “inability to feel”
3.4 ± 1.0; “pessimistic thoughts” 2.8 ± 1.1; and “suicidal
thoughts” 2.0 ± 1.2.
Anxiety assessed with the Covi scale presented a mean
score of 6.2 ± 2 points. The psychiatric history showed that
11.7% of the patients had an additional psychiatric diagnosis
(33.9% neurosis, 19.6% addiction, 17.6% personality
disorder, 14.8% psychosis, 8.3% eating disorder, 5.2%
manic episode and cyclothymia, and 0.6% unspecified).
At 6 weeks (measured by MADRS and
CGI-I)
MADRS. Figure 1 shows that 91% of the patients presented
a sustained improvement of –15% MADRS baseline score
reduction, and that 55% of the patients presented a sustained
response of –50% MADRS baseline score reduction after 6
weeks of treatment. In contrast, only 30.9% of the patients
obtained a complete remission.
Figure 1 Sustained improvement and response. The percentage of patients with
sustained –15%, –25%, –50% score reduction during the trial. Ninety-one percent
of the patients achieve a sustained –15% score reduction at 6 weeks.
Abbreviation: MADRS, Montgomery-Asberg Depression Rating Scale.Neuropsychiatric Disease and Treatment 2005:1(1) 62
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About one-third (n = 1694) of the patients were not
treated with co-medication, such as benzodiazepines,
hypnotics, and other psychotropic medications. Co-
medication with hypnotics and antianxiety agents did not
improve the antidepressant response. (The subgroup of
patients with co-medications presented higher anxiety and
depression scores at baseline compared with the subgroup
without co-medication.)
CGI-I. Figure 2 shows the survival analysis of “≥ 1-point
improvement” on the CGI-I scale. After 6 weeks of treatment,
the cumulative proportion of surviving was 4.3%, thus
indicating that more than 95% of the patients presented at
least a 1-point increase on the CGI-I scale by the end of the
study.
CGI-I scores and the MADRS scores were highly
correlated throughout the study (r = 0.77, r = 0.74, r = 0.75
at 1, 2, 6 weeks, respectively; see Figure 7), indicating that
the lack of rater training did not lead to unreliability in
scoring in this very large sample.
Severity of depression and response to
mirtazapine
Figure 3 shows the survival curves of –50% MADRS
sustained response for the different MADRS baseline
severity scores: < 25, 25–30, 30–35, 35–40, > 40. The
therapeutic response was closely related to the baseline
severity score of depression: the higher the baseline scores,
the larger was the proportion of responders (p = 0.001).
Response at 6 weeks in different forms
of clinically characterized depression
Survival analysis of sustained –50% MADRS response did
not differ in a series of subtypes of depression. The
characteristics studied were the four DSM-IV specifiers:
melancholia (with: n = 739 vs without: n = 3952, p = 0.19);
atypical depression (with: n = 301 vs without: n = 4390,
p = 0.11); recurrent depression (with: n = 2221 vs without:
n = 2505, p = 0.08); and the severity specifier (mild: n = 66,
moderate: n = 1655, severe without psychotic symptoms:
n = 2734, severe with psychotic symptoms: n = 106, p = 0.10
in the global comparison). Figure 4 shows the response
(–50% MADRS) in the 4 severity subgroups. In the subgroup
with severe psychotic symptoms (n = 109), response rates
were significantly lower (p = 0.01) compared with the other
subgroups (n = 4654 mild, moderate, and severe without
psychotic symptoms).
Figure 2 Survival analysis of “at least 1-point improvement” on the CGI-I scale.
The survival analysis of “at least 1-point improvement” on the CGI-I shows that
around 82% of the patients improved within 2 and 95% within 6 weeks.
Abbreviation: CGI, Clinical Global Improvement rating scale.
Figure 3 Survival analysis of sustained –50% MADRS response for different
baseline severity scores. The –50% MADRS sustained response is related to
baseline score. The higher the baseline scores, the larger the response.
Figure 4 Survival analysis of sustained –50% MADRS response in depression
characterized by severity (DSM-IV specifier: 1 = mild, 2 = moderate, 3 = severe
without psychotic symptoms, 4 = severe with psychotic symptoms). The –50%
MADRS sustained response is comparable in the severity subgroups defined by
the DSM-IV severity-specifier.Neuropsychiatric Disease and Treatment 2005:1(1) 63
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Similarly, survival analysis of sustained response showed
no differences between other clinically defined subgroups
of depressive patients, such as DSM-IV postpartum
depression (with: n = 18 vs without: n = 3211, p = 0.17);
seasonal depression (with: n = 305 vs without: n = 1973,
p = 0.79); or characteristics selected from the patients’
previous psychiatric history, such as a history of previous
suicide attempts (with: n = 998 vs without: n = 3770,
p = 0.28); and the diagnosis of bipolar spectrum (with: n = 25
vs without: n = 4745, p < 0.75). Figure 5 shows the response
(–50% MADRS) in the subgroups of patients with and
without bipolar spectrum.
Chronology of response: early
improvement and speed of response
MADRS global score
Using LOCF for the treatment of missing data, the mean
percentage score change was –18.5 ± 18% after 1 week,
–33.2 ± 25% after 2 weeks, and –46.1 ± 31% after 6 weeks
of treatment. The proportion of patients with a sustained
20% improvement was 28.1% after 1 week, 55% after 2
weeks, and 75.4% after 6 weeks. The speed of improvement
(percent change/day of treatment in the ITT population)
differed during the trial: it was numerically larger in the
first week compared with the following weeks. The speed
of improvement was 2.65% per day during the first week,
2.14% during the second week, and 0.46% during weeks 3
to 6. Most of the treatment effect was seen during the first 2
weeks. The change after 1 week is clinically relevant.
Patients displayed improvement immediately after entering
into the study, with the maximum change during the first 2
weeks and with further improvement occurring at much
slower rates.
MADRS item scores
Global scores of depression merge qualitatively different
aspects of the depressive syndrome into 1 single quantity.
By contrast, individual item analysis has its focus on these
differences. We found the MADRS items to present very
different mean baseline scores, ranging from 2.0 points for
suicidal thoughts to 3.8 points for apparent and reported
sadness (see baseline results). Taking this baseline variation
into account, we compared items in terms of their percentage
baseline score reduction or we compared items after
stratification (comparison of items with equal baseline
score).
Comparison of “suicidal thoughts” item with
“apparent sadness” item
The percentage baseline score reduction for “suicidal
thoughts” was larger than for “apparent sadness” at all
assessment points: 22.6 ± 38% vs 17.7 ± 25% after 1 week,
37.7 ± 44% vs 33.8 ± 30% after 2 weeks, and 50.9 ± 48% vs
47.5 ± 36% after 6 weeks of treatment (n = 4380, p < 0.0001).
“Suicidal thoughts” item with different baseline
scores
The baseline score of “suicidal thoughts” decreased quickly.
The speed of improvement (percent score reduction per day)
is given in Table 1 after 1, 2, and 6 weeks for each baseline
score (ranging from 1 to 6). Speed of change is numerically
higher during the first week in comparison with the
following weeks. Indication of the way score decreases can
also be given by the theoretical best fit curve: the best fit is
quadratic (when baseline scores range from 2 to 6) or even
cubic (when baseline scores are 3 or 4).
Comparison between patients with “suicidal
thoughts”, “reduced sleep” and “apparent
sadness”, and a baseline score of 3
The subgroups of patients in the ITT population with a
baseline score of 3 differed in size for the three MADRS
items “observed sadness” (n = 1065), “reduced sleep”
(n = 899), and “suicidal thoughts” (n = 576), and were
subjected to separate survival analyses. Figure 6 shows the
survival analysis of “≥ 1-point decrease” for these three
items. The proportion of patients showing a score reduction
of at least 1 point was larger for the subgroup of patients
with “suicidal thoughts” compared with the 2 other
Figure 5 Survival analysis of sustained –50% MADRS response in depression
characterized by bipolar features (as reported in the patient’s previous
psychiatric history). The –50% MADRS sustained response is similar (not
significant) in the bipolar/no bipolar features groups. (Bipolar features are
defined by a history of cyclothymia or manic/hypomanic episodes.)
DayNeuropsychiatric Disease and Treatment 2005:1(1) 64
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subgroups of patients with “apparent sadness” or “reduced
sleep” item.
Covi scale global score
The score reduction was –22.6 ± 36% after 1 week,
–40.0 ± 41% after 2 weeks, and –51.5 ± 47% after 6 weeks
of treatment (ITT with LOCF), thus indicating an early
anxiety reduction under mirtazapine.
The predictive value of early improve-
ment (at 1 week) for response at
6 weeks
MADRS and CGI-I
“Response” after 6 weeks of treatment was defined either
as a sustained 50% MADRS baseline score reduction or a
sustained 2-point increase (large improvement) on the
CGI-I scale. MADRS and CGI-I scores were strongly
correlated (Pearson coefficient: r = 0.77, 0.74 and 0.75 after
1, 2, and 6 weeks respectively). Figure 7 shows these
correlations after 1 week.
Prediction of the response at 1 week
Early improvement during the first two weeks of treatment
predicted patient response at the end of the study (6 weeks)
at surprisingly high rates of correctly classified patients
(Table 2).
Prediction of response (–50% MADRS
baseline score reduction) after 6 weeks
Already after 1 week of treatment, a 1-point improvement
on the CGI-I scale or a 20% or 30% improvement on the
MADRS scale clearly predicted final response. With a 1-
point improvement on CGI-I scale, the percentage of
Table 1 Speed of changes for “suicidal thoughts” and best fit curves (at the different MADRS baseline scores, ranging from 1 to 6)
Score at Speed at Speed at Speed at  Theoretical curve that
baseline N week 1 week 2 week 3–6 significantly fits the data
1 1355 2.71% 2.71% 0.71% Linear
2 1735 3.78% 3.14% 0.66% Linear, quadratic
3 684 4.95% 2.85% 0.58% Linear, quadratic, cubic
4 517 5.35% 2.57% 0.66% Linear, quadratic, cubic
5 73 5.48% 3.08% 0.50% Linear, quadratic
6 21 6.95% 1.78% 0.34% Linear, quadratic
NOTE: Speed is the % of score change between 2 assessments divided by the number of days between consecutive assessments (% change/day). Speed is computed for
each MADRS baseline score selection (from 1 to 6; baseline score of 0 is not presented). Number of patients in each baseline score selection is given in the “N”
column (384 patients present a baseline score = 0). Speed is always higher at week 1 and 2 compared with weeks 3–6, and is higher or equal in week 1 compared with
week 2. For example, with a baseline score = 1, the table reads: 1355 patients presented a score of 1 MADRS point at baseline for the “suicidal thoughts” item,
with this selection the speed of change is 2.71% at week 1 and 2 and only 0.71% from week 3 to week 6. For this selection, the theoretical curve that best fits the
data is linear.
Abbreviation: MADRS, Montgomery-Asberg Depression Rating Scale.
Figure 6 Survival analysis of “≥ 1-point reduction” for the MADRS items
“apparent sadness”, “reduced sleep”, and “suicidal thoughts” among patients with
baseline scores of 3. The figure shows the improvement (≥ 1-point reduction) of
3 MADRS items. Items having a baseline score = 3. The improvement of “suicidal
thoughts” is numerically larger than the improvement of “apparent sadness” and
“reduced sleep” (descriptive statistics).
Day
Figure 7 Correlation between MADRS and CGI-I scores. CGI-I and % of
changes on the MADRS are closely related. (r = 0.77 at 1 week).
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correctly classified patients was found to be as high as
71.6%. The positive and negative predictive values were
71% (patients with a 1-point improvement after 1 week and
a response after 6 weeks), and 72% (no improvement after
1 week and no response after 6 weeks).
Prediction of response (2-point
improvement on the CGI-I scale)
after 6 weeks
After 1 week of treatment, a 1-point improvement on the
CGI-I scale correctly predicted the final response in 72.2%
of the cases. The positive predictive value was 76% (patients
with a 1-point improvement after 1 week and a response
after 6 weeks). The negative predictive value was 68% (no
improvement after 1 week and no response after 6 weeks).
Discussion
Our results have shown that:
1. Response depends on the severity of depression.
2. Response is independent of the clinical form of
depression.
3. Improvement after 1 week of treatment is clinically
meaningful and highly predictive of final response.
4. Nearly all patients benefit from treatment to some extent.
5. There is a rapid, pronounced reduction of suicidal
thoughts and anxiety under treatment.
Dependency of response on severity of
depression
Response to mirtazapine clearly depended on the severity
of depression as the responder rates increased with severity
of depression. This finding is characteristic for true
antidepressants, whereas response to placebo has been
shown to decrease with the severity of depression. This
divergence of efficacy in relation to severity is one of the
most convincing characteristics of true antidepressant effect
(Angst 1993). The fact that severely depressed psychotic
patients did not respond as well as nonpsychotic patients is
in agreement with many other antidepressant actions; in
practice, co-medication with an antipsychotic is usually
recommended.
Independence of response from the
clinical form of depression
The antidepressive activity is comparable in all clinically
characterized patient groups. No differences were found
between the subgroups diagnosed with and without
melancholic depression, atypical depression, severe
depression, postpartum depression, seasonal depression,
recurrent depression, depression with and without past
suicide attempts, or with and without bipolar features.
Therefore, response to antidepressant treatment is
independent of the clinical form of depression; the
antidepressant effect is nonspecific.
Improvement at 1 week is
clinically meaningful and predictive
of final response
After 1 week the MADRS score decreased by 18.5%. The
speed of improvement was maximal in the first week of
treatment. After 2 weeks, the rate of baseline score reduction
decreased markedly. The period during which improvement
Table 2 Early improvement as a predictor of response after 6 weeks
Improvement + 1 CGI-I –20% MADRS –30% MADRS
Time 1 week 2 weeks 1 week 2 weeks 1 week 2 weeks
Prediction at –50% + 2 –50% + 2 –50% + 2 –50% + 2 –50% + 2 –50% + 2
6 weeks MADRS CGI-I MADRS  CGI-I MADRS  CGI-I MADRS  CGI-I MADRS  CGI-I MADRS  CGI-I
Sensitivity 0.78 0.75 0.94 0.95 0.43 0.38 0.81 0.76 0.27 0.23 0.68 0.60
Specificity 0.65 0.69 0.59 0.65 0.89 0.88 0.73 0.85 0.96 0.95 0.88 0.86
+ predict.val. 0.71 0.76 0.72 0.78 0.81 0.80 0.77 0.88 0.88 0.85 0.87 0.85
– predict.val. 0.72 0.68 0.90 0.90 0.58 0.52 0.77 0.70 0.54 0.48 0.71 0.62
%correct cla 71.6 72.2 77.6 81.7 64.7 59.3 77.2 74.8 59.6 54.0 77.3 71.2
False + rate 0.35 0.31 0.41 0.35 0.11 0.12 0.27 0.15 0.04 0.05 0.12 0.14
False – rate 0.22 0.25 0.06 0.05 0.57 0.62 0.19 0.24 0.73 0.77 0.32 0.40
Area under ROC 0.71 0.72 0.77 0.79 0.66 0.63 0.77 0.75 0.62 0.59 0.78 0.73
NOTE: Improvement at 1 and 2 weeks strongly predicts the response at 6 weeks. A 1-point increase on the CGI-I at 1 week correctly predicted the final response
(2-points improvement on the CGI-I) in 72.2 % of the cases.
Abbreviations: CGI-I, clinical global improvement; MADRS, Montgomery-Asberg Depression Rating Scale; cla, classification. Bolded numbers are those presented in
the text.Neuropsychiatric Disease and Treatment 2005:1(1) 66
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is > 2%/day only lasted 2 weeks. These results confirm
previous studies and meta-analyses in which the clinical
effect of antidepressant treatments differed from placebo
within 1 week and even on the fourth day of treatment
(Stassen et al 1993, 1996; Stassen and Angst 1998). Early
improvement did not result from lateral effects (stimulation
or sedation) since it strongly predicted response after 6
weeks of treatment.
The early therapeutic effect of antidepressants is
consistent with recent research that showed changes in
noradrenergic and serotonergic neurotransmission produced
an immediate effect. Enhancing neurotransmission with
antidepressants induced positive behaviors within three
hours even in healthy subjects. Administration of
noradrenergic (Harmer, Hill, et al 2003) or serotonergic
(Harmer, Bhagwagar, et al 2003) antidepressants increased
the facial recognition of happiness by healthy volunteers.
Noradrenergic antidepressants also promoted cooperative
behavior. An acute dose of reboxetine increased both
cooperative communication and cooperative behavior (Tse
and Bond 2002a).
In contrast, reducing neurotransmission in the
noradrenaline or in the serotonin system induced negative
effects, such as an acute depressive relapse (Heninger et al
1996; Delgado and Moreno 1999; Delgado et al 2002),
which occurred especially when the monoamine systems
had been previously stimulated by an antidepressant and
accordingly the postsynaptic receptors down-regulated.
The improvement seen after 1 week was highly
predictive of the final response. With the 7-point CGI-I scale
a “1-point increase or more” was found to be the most
efficient tool to predict response. At 1 week a “≥ 1-point
increase” allowed correct classification of responders in
71.6% (when the response was defined as a “50% MADRS
reduction”), or in 72.2% (when the response was defined as
“large improvement” with the CGI-I scale). According to
Figure 7, a 1-point increase in CGI-I corresponds roughly
to a 20% decrease in MADRS, a clinically meaningful
improvement especially during the early phase of treatment.
Generally, when improvement is observed throughout
the first week of treatment, it is very likely that the complete
response will be observed within 6 weeks. Early improve-
ment could serve clinicians as a guideline in deciding about
increased dosage, augmentation, or change of medication
in unresponsive patients. The use of a depression scale in
everyday private practice is, however, rather troublesome
and time-consuming except for the intuitive, easy-to-use
CGI-I scale. Empirical data suggest keeping the treatment
unchanged if improvement is observed (at least a small
improvement which corresponds to a 1-point increase with
the CGI-I), and to enhance dosage if improvement is not
observed within the first week.
Nearly all patients benefit from
treatment to some degree
Minimal improvement, defined as a “≥ 1-point improve-
ment” on the CGI-I scale, was observed in more than 95%
of patients by the end of the study. Nearly all patients were
improved, at least slightly, during the trial. On the other
hand, the degree of response was far from complete, since
less than 60% of the patients displayed a sustained response
(50% reduced MADRS score).
The major finding of this study is that the antidepressant
effect appears to be a generalized effect benefiting nearly
all patients, independent of the clinical form of depression.
This generalized effect can also be observed in healthy
subjects during chronic treatment. Recent research showed
in healthy volunteers that chronic administration of
noradrenergic antidepressant promoted social bonding (Tse
and Bond 2003), and that chronic administration of
serotonergic antidepressant increased affiliative behavior
(Tse and Bond 2002b).
In contrast, the antidepressant effect is limited in time.
In our study, the improvement period (rate of improvement
> 2%/day) lasted only 2 weeks. Subsequent improvement
was much slower (< 0.5%/day). This slowdown presumably
resulted from homeostatic regulation, since there is still
“room for improvement” after the initial 2-week window.
The 30.9% remission rate at 6 weeks shows clearly that
antidepressant response is limited.
The homeostatic regulation keeps mood variations
under strict control and opposed to pharmacological
manipulations. The regulation includes the limited
availability of neurotransmitters (Moskowitz et al 2001),
the 5HT-moduline system (Fillion et al 1997), and many
monoamine negative feedback mechanisms such as the
decreased firing rate observed at the beginning of a selective
serotonin reuptake inhibitor (SSRI) antidepressant treatment
(Artigas 2001; Blier 2003) and the postsynaptic receptor
down-regulation that follows (after 2 weeks) increase in
neurotransmission.
Our hypothesis is that the generalized, nonspecific
antidepressant effect results from an increase in monoamine
neurotransmission that, due to homeostatic regulations, onlyNeuropsychiatric Disease and Treatment 2005:1(1) 67
Mirtazapine in depression
lasts a limited time. Could an increase in treatment dosage
after 2 weeks increase the duration of the improvement
period? Previously we showed that augmentation strategy
increased response among initial nonresponders to
fluoxetine (Ferreri et al 2001). Our testable hypothesis is
that neurotransmission could be increased for a longer period
of time if the dosage were increased daily rather than kept
constant. For example, would a 1-mg increase per day for
14 days (105 mg total) be more efficacious than 7.5 mg/day
(105 mg total) over the same time period?
Large and fast reduction of suicidal
thoughts and anxiety under treatment
Items from the MADRS can be analysed separately and
compared. Comparisons of items with different baseline
scores should be assessed by the percent change or by
stratification (comparison of items with equal baseline
score). Three negative emotions described by Ekman (1999)
are represented by some MADRS items: sadness = apparent
and reported sadness; fear = inner tension. Anger is not
directly represented by a MADRS item, but since self-
aggression and anxiety are involved in suicidal tendency,
we propose that anger is partly represented by the “suicidal
thoughts” item.
“Suicidal thoughts” item
In the ITT population, the percent score reduction of
“suicidal thoughts” is larger than for “apparent sadness”
(p < 0.0001 at all assessment times using LOCF). The
reduction of “suicidal thoughts” is observed early after the
start of treatment. At 1 week the percentage of score change
is –22.6 ± 38%, and more than 50% of the patients have a
“≥ 1-point” increase. The improvement of “suicidal
thoughts” is rapid with mirtazapine, faster than that of
“sadness”. From a pharmacological perspective, it should
be noted that mirtazapine reduces the release of cortisol
(Laakmann et al 2000) and presents a strong H1 antagonism,
both of which could account for the reduction of “suicidal
thoughts”. Although anxiety is an important clinical factor
in suicidal risk, we found that a relationship between the
two was no different from the relationship of suicidal
ideation with other MADRS items. Further study is clearly
needed of this important effect of mirtazapine on suicidal
thoughts.
Previously we have described (Lavergne et al 2001) that
for each MADRS baseline score selection (from 1 to 6) the
Area Under Curve (AUC; sum of score changes at 1, 2, and
6 weeks) of the “suicidal thoughts” item is larger than that
of the 7 other “psychic” items (apparent and reported
sadness, inner tension, concentration difficulties, lassitude,
inability to feel, pessimistic thoughts). The AUC of “suicidal
thoughts” exceeds the AUC of all “psychic” items by at least
79% when items have a baseline score = 1; 46% when the
baseline score = 2; 36% when baseline score = 3; 24% when
baseline score = 4; 24% when baseline score = 5; and by 12%
when baseline score = 6.
Anxiety
Anxiety assessed with the Covi scale is rapidly reduced by
mirtazapine. At 1 week the score change is –22.6 ± 36%.
Sorensen et al (1985) have observed this antianxiety effect
within a day. Mirtazapine presents a “peaceful” emotional
profile with a rapid reduction of fear and anger as
demonstrated by the fast reduction of anxiety and “suicidal
thoughts”.
Conclusion
Mirtazapine is equally effective for all clinical forms of
depression and benefits nearly all patients to a certain degree.
The improvement is clinically meaningful in the first week,
predictive of the final response, and should guide treatment
dosage as most of the therapeutic effect is observed during
the first 2 weeks.
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